• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

982
82
61
58
47

COUNTRY

56
19
10
6
5

CATEGORIES

  • 82
  • 120
  • 66
  • 66
  • 36
  • 37
  • 11
  • 11
  • 12
  • 18

PRICE

550
813
1,789
2,612

PUBLISHED

64
255
736
2,612

PRODUCT TYPE

2,461
76
62
12
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE

Rhabdomyosarcoma - Pipeline Review, H1 2013

Rhabdomyosarcoma - Pipeline Review, H1 2013 Summary 'Rhabdomyosarcoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

June 2013
FROM

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2013

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2013 Summary 'Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2013', provides an overview...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Current and Future Players

PharmaPoint: Non-Small Cell Lung Cancer - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Non-Small Cell Lung Cancer - Current and Future Players”. The...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

Ramucirumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Ramucirumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men...

June 2013
FROM

Onartuzumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Onartuzumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men...

June 2013
FROM

Yervoy (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Yervoy (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women....

June 2013
FROM

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2013

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2013 Summary 'Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

June 2013
FROM

Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013

Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013 Summary 'Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022 Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men...

June 2013
FROM

Necitumumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Necitumumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Italy Drug Forecast and Market Analysis to 2022

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women Historically, the treatment paradigm has centered around chemotherapy However, the...

June 2013
FROM

Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - France Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

Xalkori (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Xalkori (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

Halaven ( Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Halaven ( Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - Japan Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - Spain Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM

Alimta (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Alimta (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women....

June 2013
FROM
Loading Indicator

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)